MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Nektar Therapeutics

Fechado

0.58 -10.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.57

Máximo

0.66

Indicadores-chave

By Trading Economics

Rendimento

44M

7.3M

Vendas

5.1M

29M

EPS

-0.15

Margem de lucro

24.888

Funcionários

61

EBITDA

48M

17M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+619.7% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-30M

137M

Abertura anterior

11.35

Fecho anterior

0.58

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Nektar Therapeutics Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 23:04 UTC

Principais Notícias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 de abr. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 de abr. de 2025, 18:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 de abr. de 2025, 23:43 UTC

Conversa de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 de abr. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 de abr. de 2025, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 21:43 UTC

Principais Notícias
Ganhos

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de abr. de 2025, 20:43 UTC

Conversa de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 de abr. de 2025, 20:34 UTC

Principais Notícias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 de abr. de 2025, 20:23 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 de abr. de 2025, 19:21 UTC

Conversa de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 de abr. de 2025, 19:15 UTC

Conversa de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 de abr. de 2025, 18:39 UTC

Conversa de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 de abr. de 2025, 18:38 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 18:30 UTC

Principais Notícias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 de abr. de 2025, 18:20 UTC

Conversa de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 de abr. de 2025, 18:18 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:17 UTC

Conversa de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 de abr. de 2025, 18:04 UTC

Conversa de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 de abr. de 2025, 17:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Nektar Therapeutics Previsão

Preço-alvo

By TipRanks

619.7% parte superior

Previsão para 12 meses

Média 4.75 USD  619.7%

Máximo 7 USD

Mínimo 1 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Nektar Therapeutics - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

5

Comprar

2

Manter

1

Vender

Pontuação Técnica

By Trading Central

0.6373 / 0.7374Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.